News
LZAGY
65.99
+1.08%
0.71
Weekly Report: what happened at LZAGY last week (0907-0911)?
Weekly Report · 3d ago
Lonza Group Ltd (LONN) Gets a Buy from Barclays
TipRanks · 09/08 06:55
Weekly Report: what happened at LZAGY last week (0831-0904)?
Weekly Report · 09/07 09:11
Weekly Report: what happened at LZAGY last week (0824-0828)?
Weekly Report · 08/31 09:11
Weekly Report: what happened at LZAGY last week (0817-0821)?
Weekly Report · 08/24 09:12
Artisan Global Opportunities Fund Q2 2026 Portfolio Review
Seeking Alpha · 08/19 05:10
Weekly Report: what happened at LZAGY last week (0810-0814)?
Weekly Report · 08/17 09:12
Weekly Report: what happened at LZAGY last week (0803-0807)?
Weekly Report · 08/10 09:11
Barclays Sticks to Its Buy Rating for Lonza Group Ltd (LONN)
TipRanks · 08/07 05:46
Weekly Report: what happened at LZAGY last week (0727-0731)?
Weekly Report · 08/03 09:11
RBC Capital Sticks to Its Buy Rating for Lonza Group Ltd (LONN)
TipRanks · 08/03 06:36
Weekly Report: what happened at LZAGY last week (0720-0724)?
Weekly Report · 07/27 09:12
Lonza Group Ltd (LONN) Gets a Buy from Bernstein
TipRanks · 07/25 03:35
Lonza price target raised to CHF 760 from CHF 720 at RBC Capital
TipRanks · 07/23 16:15
Goldman Sachs Reaffirms Their Buy Rating on Lonza Group Ltd (LONN)
TipRanks · 07/23 07:25
Lonza Group Ltd (LONN) Receives a Buy from RBC Capital
TipRanks · 07/23 06:35
Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside
Seeking Alpha · 07/23 02:46
Lonza Earnings Call Highlights Growth, Margins, Strategy
TipRanks · 07/23 00:04
Here are the major earnings before the open Wednesday
Seeking Alpha · 07/21 22:00
Weekly Report: what happened at LZAGY last week (0713-0717)?
Weekly Report · 07/20 09:11
More
Webull provides a variety of real-time LZAGY stock news. You can receive the latest news about Lonza Gro through multiple platforms. This information may help you make smarter investment decisions.
About LZAGY
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.